Pilot Study: Efficacy and Safety of Polycaprolactone Collagen Stimulator for Middle Third of the Face.

Background: Facial aging is a multifaceted process involving structural changes in deeper tissues alongside skin alterations. Dermal fillers, including hyaluronic acid and non-hyaluronic acid variants, have emerged as key tools in addressing these changes, offering safe, effective, and minimally invasive solutions. Polycaprolactone (PCL) is a biocompatible, biodegradable polymer with remarkable collagen-stimulating properties. Methods: This pilot study explored the efficacy and safety of liquid PCL-based filler in rejuvenating the middle third of the face in 30 patients during a 6-month period, who underwent 2 treatments with PCL filler using a 25G cannula. Results: The results demonstrate significant improvements in skin quality and volume, with high patient satisfaction rates. Although adverse events were mild and transient, careful injection techniques are recommended to mitigate risks. The gradual dissipation of the PCL-based filler induced the formation of new collagen, ensuring a prolonged volumizing effect in the middle third of the face. Conclusions: The ability of PCL to stimulate collagen production offers promising prospects for long-term facial rejuvenation, underscoring its importance in modern aesthetic medicine.